comparemela.com

Latest Breaking News On - Btk inhibitors - Page 1 : comparemela.com

Dr Sotomayor on the Integration of BTK Inhibitors into the CLL Treatment Arsenal

Eduardo Sotomayor, MD, discusses the current arsenal of BTK inhibitors in chronic lymphocytic leukemia.

Javier pinillaEduardo sotomayorMoffitt cancer centerCancer instituteTampa general hospitalScience summitChronic lymphocytic leukemiaOnclive tvBtk inhibitors

Primary Analysis of the SYMPATICO trial in Mantle Cell Lymphoma

Focusing on mantle cell lymphoma, Lori A. Leslie, MD, reviews the primary analysis of the SYMPATICO trial investigating ibrutinib-venetoclax combination therapy.

Lori leslieJamesk mccloskeyGloria leslieHackensack university medical centerJohn theurer cancer centerResearch programsPeer exchangeHackensack university medicalAssociate professorIndolent lymphomaWhile brutonMash 2023Sympatico studySympatico trialMantle cell lymphomaBtk inhibitors

Key Considerations for Treating Patients Diagnosed With CLL and SLL

Medical experts provide their final thoughts regarding key treatment considerations for CLL and SLL.

Jennifer woyachTara graffRyan haumschildDeborah stephensBryan jacobsPeer exchangeBtk inhibitorsCardiac eventsToxicity profileCart therapyJcdk4 6 inhibitorAnti cd38Social determinants of healthFinancial burdenFinancial toxicityEconomic burden

Dr Pearse on the BOVen Trial of BTK Inhibitor Combinations in TP53-Mutant MCL

William B. Pearse, MD, discusses the significance of the ongoing phase 2 BOVen trial in TP53-mutant mantle cell lymphoma.

United statesSan diegoWilliamb pearseUniversity of californiaSan diego school of medicineSan diego schoolBtk inhibitorsPatients with relapsed refractory mantle cell lymphomaSan diego school of medicineTp53 mutation

SOC Drugs Provide Strong Foundation For Effective Combinations in Hematologic Malignancies

Catherine C. Coombs, MD, discusses future directions for BTK inhibitors in chronic lymphocytic leukemia and combination therapies in myelofibrosis.

United statesCatherinec coombsAngelag fleischmannNaveen pemmarajuJoshuaf zeidnerInternational consensus classificationSchool of medicineDivision of hematologyDepartment of medicineWorld health organizationUniversity of california irvineOnclive institutional perspectivesCalifornia irvineNew england journalChapel hillInternational consensus

vimarsana © 2020. All Rights Reserved.